Experimental gonococcal urethritis and reinfection with homologous gonococci in male volunteers

Sexually Transmitted Diseases

Volumn 28, Issue 10, 2001, Pages 555-564

  Schmidt, Katherine A ^a   Schneider, Herman ^a   Lindstrom, Jill A ^a   Boslego, John W ^a   Warren, Richard A ^a   Van De Verg, Lillian ^a   Deal, Carolyn D ^a   McCLain, J Bruce ^a   Griffiss, J McLeod ^b,c  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; GONOCOCCAL VACCINE MS11MKC; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPOOLIGOSACCHARIDE ANTIBODY; OLIGOSACCHARIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BACTERIAL INFECTION; BACTERIUM PILUS; CLINICAL TRIAL; GONOCOCCAL URETHRITIS; GONORRHEA; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGLOBULIN PRODUCTION; IMMUNOPATHOLOGY; INFECTION PREVENTION; INFECTION RESISTANCE; MALE; NEISSERIA GONORRHOEAE; NORMAL HUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REINFECTION; STRAIN DIFFERENCE;

EID: 0034796337     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007435-200110000-00001     Document Type: Article

References (57)

1. The contribution of reinfection to gonorrhea incidence in Alaska, 1983-1987
2. Experimental infection with Neisseria gonorrhoeae
3. Recidivism among patients with gonococcal infection presenting to a venereal disease clinic
4. Efficacy trial of a parenteral gonococcal pilus vaccine in men
5. Gonococcal vaccine studies in Inuvik
6. Gonococcal vaccines
7. Is there protective immunity to gonococcal disease?
8. The development of a neisserial pilus vaccine for gonorrhea and meningococcal meningitis
9. Epidemiologic evidence for the development of serovar-specific immunity after gonococcal infection
10. Experimental human gonococcal urethritis: 250 Neisseria gonorrhoeae MS11mkC are infectious
11. Sialylation lessens the infectivity of Neisseria gonorrhoeae MS11mkC
12. Expression of paragloboside-like lipooligosaccharides may be a necessary component of gonococcal pathogenesis in men
13. Serum antibody response in experimental human gonorrhoeae
14. Antibodies to Neisseria gonorrhoeae: A study of the urethral exudates of 232 men
15. Underlying complement deficiency in patients with disseminated gonococcal infection
16. Familial deficiency of the seventh component of complement associated with recurrent bacteremic infections due to Neisseria
17. The pathology of gonorrhoea
18. Guidelines for treatment of sexually transmitted diseases
19. Neisseria gonorrhoeae MS11mkC opacity protein expression in vitro and during human volunteer infectivity studies
20. Purification and partial characterization of the opacity-associated proteins of Neisseria gonorrhoeae
21. Protein measurement with the Folin phenol reagent
22. Cleavage of structural proteins during the assembly of the head of the bacteriophage T4
23. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications
24. Evidence of serum antibodies to Neisseria gonorrhoeae before gonococcal infection
25. Lysis of Neisseria gonorrhoeae initiated by binding of normal human IgM to a hexosamine-containing lipooligosaccharide epitope(s) is augmented by strain-specific, properdin-binding-dependent alternative complement pathway activation
26. Epidemiology of gonorrhea: Current perspectives
27. PPNG at St. Thomas Hospital: A changing provenance
28. Human experimentation with Neisseria gonorrhoeae: Rationale, methods, and implications for the biology of infection and vaccine development
29. Some factors affecting the incubation period and duration of symptoms of urethritis in men
30. An estimate of the risk of men acquiring gonorrhea by sexual contact with infected females
31. An evaluation of gonorrhea case findings in the chronically infected female
32. Serogrouping of Neisseria gonorrhoeae: Correlation of serogroup with disseminated gonococcal infection
33. Neisseria meningitidis and Neisseria gonorrhoeae bacteremia associated with C6, C7, or C8 deficiency
34. Antibody-antigen specificity in the immune response to infection with Neisseria gonorrhoeae
35. Antigenic variation during infection with Neisseria gonorrhoeae: Detection of antibodies to surface proteins in sera of patients with gonorrhea
36. Natural human antibodies to Gram-negative bacteria: Immunoglobulins G, A, and M
37. Natural and immune human antibodies reactive with antigens of virulent Neisseria gonorrhoeae Immunoglobulins G, M, and A
38. Monoclonal anti-body that recognizes an outer membrane antigen common to the pathogenic Neisseria species but not to most nonpathogenic Neisseria species
39. Neisseria lactamica and Neisseria meningitidis share lipooligosaccharide epitopes, but lack common capsular and class 1, 2, and 3 protein epitopes
40. Lipooligosaccharides (LOS) of Neisseria gonorrhoeae, Neisseria meningitidis have components that are immunochemically similar to precursors of human blood group antigens: Carbohydrate sequence specificity of the mouse monoclonal antibodies that recognize cross-reacting antigens on LOS and human erythrocytes
41. The chemistry and biology of lipooligosaccharides: The endotoxins of bacteria of the respiratory and genital mucosae
42. New paradigms for sexually transmitted diseases surveillance and field studies
43. Longitudinal evaluation of serovar-specific immunity to Neisseria gonorrhoeae
44. Gonococcal salpingitis is less likely to recur with Neisseria gonorrhoeae of the same principal outer membrane protein antigenic type
45. Antibodies to opacity proteins (Opa) correlate with a reduced risk of gonococcal salpingitis
46. Secretory IgA antibodies in the urethral exudate of men with uncomplicated urethritis due to Neisseria gonorrhoeae
47. Gonococcal pilin variants in experimental gonorrhea
48. Expression of outer membrane protein II by gonococci in experimental gonorrhea
49. Human antibody response to lipopolysaccharides from Neisseria gonorrhoeae
50. Immunogenicity of Neisseria gonorrhoeae lipooligosaccharide epitope 2C7, widely expressed in vivo with no immunochemical similarity to human glycosphingolipids
51. Experimental immunization with a monoclonal anti-idiotope antibody that mimics the Neisseria gonorrhoeae lipooligosaccharide epitope 2C7
52. Conservation of the lipooligosaccharide synthesis locus lgt among strains of Neisseria gonorrhoeae: Requirement for lgtE in synthesis of the 2C7 epitope and of the β-chain of strain 15253
53. Epitope expression and partial structural characterization of F62 lipooligosaccharide (LOS) of Neisseria gonorrhoeae: IgM monoclonal antibodies (3F11 and 1-1-M) recognize nonreducing terminus of F62 LOS components
54. Structural analysis of lipooligosaccharide produced by Neisseria gonorrhoeae strain MS11MK (variant A)
55. Antigenic and physical diversity of Neisseria gonorrhoeae lipooligosaccharides
56. Heterogeneity of molecular size and antigenic expression within the lipooligosaccharides of individual strains of Neisseria gonorrhoeae and Neisseria meningitidis